Funder: METAvivor
Due Dates (Anticipated): March 2027 (Letter of Intent) | August 2027 (Invited full application)
Funding Amounts: Up to $200,000 total over two years, capped at $100,000 per year
Summary: Supports early-career investigators pursuing basic, translational, and clinical research to improve outcomes for people living with established metastatic breast cancer.
Key Information: Meaningful patient advocate involvement is required; full applications are by invitation only.
Description
METAvivor’s Early Career Investigator Award supports novel, high-quality research addressing critical problems and barriers in metastatic breast cancer. It funds discovery and early-phase basic, translational, and clinical work by emerging investigators, with a clear focus on established breast cancer metastases and potential benefit for people already living with stage IV disease.
Priority goes to projects that could directly improve clinical outcomes or establish a conceptual foundation for better treatments, including mechanistic and preclinical animal studies. Relevant work includes treatment-response biomarkers, novel therapeutic targets, treatment regimens, animal and organoid models, metastatic progression, health disparities, treatment side effects, and quality of life. Prevention-focused research and diagnostic studies are excluded, except novel diagnostic tools that inform understanding of metastatic cancer progression.
